Universityhospital Tuebingen

Tübingen 72076

2 studies enrolling now · 13 studies all time

What they study most

Acute Ischemic Stroke, Adult-type Diffuse Gliomas, Brain Neoplasms, Cerebral Stroke, Cutaneous Squamous Cell Carcinoma, Depressive Disorder, Major, Glioblastoma, Glioma, Intracerebral Hemorrhage, Metastatic Cholangiocarcinoma, Multiple System Atrophy, Parkinson Disease

Studies at this site

• Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke — Recruiting now
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 — Recruiting now
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Running, not enrolling
• [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes — Completed
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Running, not enrolling
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations — Stopped early
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• Noninterventional Study Evaluating Parkinson's Disease Diary Use — Running, not enrolling
• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age — Stopped early
• Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer — Running, not enrolling
• Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease — Stopped early
• Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease — Stopped early